Corvus Pharmaceuticals, Inc. financial data

Symbol
CRVS on Nasdaq
Industry
Pharmaceutical Preparations
Location
863 Mitten Road, Suite 102, Burlingame, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 194 % -55.9%
Debt-to-equity 54.1 % +185%
Return On Equity -168 % -176%
Return On Assets -109 % -113%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 64.3M shares +31%
Common Stock, Shares, Outstanding 62.6M shares +27.6%
Entity Public Float 84.2M USD +146%
Common Stock, Value, Issued 6K USD +20%
Weighted Average Number of Shares Outstanding, Basic 66.7M shares +36.2%
Weighted Average Number of Shares Outstanding, Diluted 66.7M shares +36.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 17.4M USD +4.84%
General and Administrative Expense 7.68M USD +12.8%
Operating Income (Loss) -25.1M USD -7.14%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -56.8M USD -88.2%
Earnings Per Share, Basic -0.92 USD/shares -43.8%
Earnings Per Share, Diluted -0.92 USD/shares -43.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.68M USD -76.7%
Cash, Cash Equivalents, and Short-term Investments 41.7M USD +29.5%
Accounts Receivable, after Allowance for Credit Loss, Current 70K USD +536%
Other Assets, Current 633K USD +196%
Assets, Current 42.9M USD +29.7%
Property, Plant and Equipment, Net 171K USD -35.2%
Operating Lease, Right-of-Use Asset 284K USD -80%
Other Assets, Noncurrent 252K USD +183%
Assets 58.8M USD +13.2%
Accounts Payable, Current 1.87M USD +33.4%
Employee-related Liabilities, Current 610K USD -18.8%
Liabilities, Current 46.4M USD +536%
Operating Lease, Liability, Noncurrent 354K USD -79%
Liabilities 46.4M USD +506%
Accumulated Other Comprehensive Income (Loss), Net of Tax -738K USD +48.9%
Retained Earnings (Accumulated Deficit) -385M USD -17.3%
Stockholders' Equity Attributable to Parent 12.4M USD -72%
Liabilities and Equity 58.8M USD +13.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.16M USD +36.4%
Net Cash Provided by (Used in) Investing Activities 4.6M USD
Common Stock, Shares Authorized 290M shares 0%
Common Stock, Shares, Issued 62.6M shares +27.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -5.16M USD -47.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.68M USD -76.7%
Deferred Tax Assets, Valuation Allowance 83M USD +8.71%
Deferred Tax Assets, Gross 83.3M USD +8.25%
Operating Lease, Liability 354K USD
Payments to Acquire Property, Plant, and Equipment 34K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -56.1M USD -84.4%
Lessee, Operating Lease, Liability, to be Paid 358K USD
Property, Plant and Equipment, Gross 4.79M USD -2.86%
Operating Lease, Liability, Current 354K USD -73.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.39M USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.43M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 280K USD -49.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.43M USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 59.3M USD +5.86%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 12.8M USD +0.81%
Operating Lease, Payments 1.88M USD +5.98%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 23K USD -59.6%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 2.76M USD +25.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%